Eph receptors and ephrin signaling pathways: A role in bone homeostasis

International Journal of Medical Sciences

Volumn 5, Issue 5, 2008, Pages 263-272

  Edwards, Claire M ^a   Mundy, Gregory R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone remodeling; Coupling; Eph receptors; Ephrins; Osteoblast; Osteoclast

Indexed keywords

EPHRIN; EPHRIN B1; EPHRIN B2; EPHRIN RECEPTOR; LIGAND;

BIOLOGICAL ACTIVITY; BIOLOGY; BONE DISEASE; BONE HOMEOSTASIS; BONE REMODELING; CELL SURFACE; HOMEOSTASIS; HORMONAL REGULATION; IMMUNE FUNCTION TEST; IMMUNOREGULATION; METASTASIS; NEOPLASM; NERVE CELL DIFFERENTIATION; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

EID: 51449104971     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.5.263     Document Type: Review

References (94)

1. Hirai H, Maru Y, Hagiwara K, et al. A novel putative tyrosine kinase receptor encoded by the eph gene. Science. 1987; 238: 1717-1720.
2. Kullander K and Klein R. Mechanisms and functions of eph and ephrin signalling. Nat Rev Mol Cell Biol. 2002; 3: 475-486.
3. Himanen JP, Chumley MJ, Lackmann M, et al. Repelling class discrimination: Ephrin-a5 binds to and activates ephb2 receptor signaling. Nat Neurosci. 2004; 7: 501-509.
4. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol. 2005; 6: 462-475.
5. Egea J and Klein R. Bidirectional eph-ephrin signaling during axon guidance. Trends Cell Biol. 2007; 17: 230-238.
6. Stein E, Lane AA, Cerretti DP, et al. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev. 1998; 12: 667-678.
7. Miao H, Burnett E, Kinch M, et al. Activation of epha2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol. 2000; 2: 62-69.
8. Lai KO, Chen Y, Po HM, et al. Identification of the jak/stat proteins as novel downstream targets of epha4 signaling in muscle: Implications in the regulation of acetylcholinesterase expression. Biol Chem J. 2004; 279: 13383-13392.
9. Shamah SM, Lin MZ, Goldberg JL, et al. Epha receptors regulate growth cone dynamics through the novel guanine nucleotide exchange factor ephexin. Cell. 2001; 105: 233-244.
10. Lawrenson ID, Wimmer-Kleikamp SH, Lock P, et al. Ephrin-a5 induces rounding, blebbing and de-adhesion of epha3-expressing 293t and melanoma cells by crkii and rho-mediated signalling. Cell Sci J. 2002; 115: 1059-1072.
11. Irie F and Yamaguchi Y. Ephb receptors regulate dendritic spine development via intersectin, cdc42 and n-wasp. Nat Neurosci. 2002; 5: 1117-1118.
12. Penzes P, Beeser A, Chernoff J, et al. Rapid induction of dendritic spine morphogenesis by trans-synaptic ephrinb-ephb receptor activation of the rho-gef kalirin. Neuron. 2003; 37: 263-274.
13. Zou JX, Wang B, Kalo MS, et al. An eph receptor regulates integrin activity through r-ras. Proc Natl Acad Sci U S A. 1999; 96: 13813-13818.
14. Miao H, Wei BR, Peehl DM, et al. Activation of epha receptor tyrosine kinase inhibits the ras/mapk pathway. Nat Cell Biol. 2001; 3: 527-530.
15. Bruckner K, Pasquale EB and Klein R. Tyrosine phosphorylation of transmembrane ligands for eph receptors. Science. 1997; 275: 1640-1643.
16. Holland SJ, Gale NW, Mbamalu G, et al. Bidirectional signalling through the eph-family receptor nuk and its transmembrane ligands. Nature. 1996; 383: 722-725.
17. Cowan CA and Henkemeyer M. The sh2/sh3 adaptor grb4 transduces b-ephrin reverse signals. Nature. 2001; 413: 174-179.
18. Lu Q, Sun EE, Klein RS and Flanagan JG. Ephrin-b reverse signaling is mediated by a novel pdz-rgs protein and selectively inhibits g protein-coupled chemoattraction. Cell. 2001; 105: 69-79.
19. Davy A, Gale NW, Murray EW, et al. Compartmentalized signaling by gpi-anchored ephrin-a5 requires the fyn tyrosine kinase to regulate cellular adhesion. Genes Dev. 1999; 13: 3125-3135.
20. Hornberger MR, Dutting D, Ciossek T, et al. Modulation of epha receptor function by coexpressed ephrina ligands on retinal ganglion cell axons. Neuron. 1999; 22: 731-742.
21. Marquardt T, Shirasaki R, Ghosh S, et al. Coexpressed epha receptors and ephrin-a ligands mediate opposing actions on growth cone navigation from distinct membrane domains. Cell. 2005; 121: 127-139.
22. Carvalho RF, Beutler M, Marler KJ, et al. Silencing of epha3 through a cis interaction with ephrina5. Nat Neurosci. 2006; 9: 322-330.
23. Schmitt AM, Shi J, Wolf AM, et al. Wnt-ryk signalling mediates medial-lateral retinotectal topographic mapping. Nature. 2006; 439: 31-37.
24. Dalva MB, Takasu MA, Lin MZ, et al. Ephb receptors interact with nmda receptors and regulate excitatory synapse formation. Cell. 2000; 103: 945-956.
25. Tanaka M, Kamata R and Sakai R. Epha2 phosphorylates the cytoplasmic tail of claudin-4 and mediates paracellular permeability. Biol Chem J. 2005; 280: 42375-42382.
26. Tanaka M, Kamata R, Sakai R. Phosphorylation of ephrin-b1 via the interaction with claudin following cell-cell contact formation. Embo J. 2005; 24: 3700-3711.
27. Yamaguchi Y and Pasquale EB. Eph receptors in the adult brain. Curr Opin Neurobiol. 2004; 14: 288-296.
28. Santiago A and Erickson CA. Ephrin-b ligands play a dual role in the control of neural crest cell migration. Development. 2002; 129: 3621-3632.
29. Ethell IM, Irie F, Kalo MS, et al. Ephb/syndecan-2 signaling in dendritic spine morphogenesis. Neuron. 2001; 31: 1001-1013.
30. Dalva MB, McClelland AC and Kayser MS. Cell adhesion molecules: Signalling functions at the synapse. Nat Rev Neurosci. 2007; 8: 206-220.
31. Du J, Fu C and Sretavan DW. Eph/ephrin signaling as a potential therapeutic target after central nervous system injury. Curr Pharm Des. 2007; 13: 2507-2518.
32. Liu X, Hawkes E, Ishimaru T, et al. Ephb3: An endogenous mediator of adult axonal plasticity and regrowth after cns injury. Neurosci J. 2006; 26: 3087-3101.
33. Brantley-Sieders D, Schmidt S, Parker M and Chen J. Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des. 2004; 10: 3431-3442.
34. Kumar SR, Singh J, Xia G, et al. Receptor tyrosine kinase ephb4 is a survival factor in breast cancer. Am Pathol J. 2006; 169: 279-293.
35. Zelinski DP, Zantek ND, Stewart JC, et al. Epha2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 2001; 61: 2301-2306.
36. Brantley-Sieders DM, Fang WB, Hicks DJ, et al. Impaired tumor microenvironment in epha2-deficient mice inhibits tumor angiogenesis and metastatic progression. Faseb J. 2005; 19: 1884-1886.
37. Fang WB, Brantley-Sieders DM, Parker MA, et al. A kinase-dependent role for epha2 receptor in promoting tumor growth and metastasis. Oncogene. 2005; 24: 7859-7868.
38. Easty DJ, Hill SP, Hsu MY, et al. Up-regulation of ephrin-a1 during melanoma progression. Int Cancer J. 1999; 84: 494-501.
39. Walker-Daniels J, Coffman K, Azimi M, et al. Overexpression of the epha2 tyrosine kinase in prostate cancer. Prostate. 1999; 41: 275-280.
40. Kinch MS, Moore MB and Harpole DH. Predictive value of the epha2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res. 2003; 9: 613-618.
41. Orsulic S and Kemler R. Expression of eph receptors and ephrins is differentially regulated by e-cadherin. Cell Sci J. 2000; 113 (Pt 10): 1793-1802.
42. Zantek ND, Azimi M, Fedor-Chaiken M, et al. E-cadherin regulates the function of the epha2 receptor tyrosine kinase. Cell Growth Differ. 1999; 10: 629-638.
43. Wang HU, Chen ZF and Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-b2 and its receptor eph-b4. Cell. 1998; 93: 741-753.
44. Brantley DM, Cheng N, Thompson EJ, et al. Soluble eph a receptors inhibit tumor angiogenesis and progression in vivo. Oncogene. 2002; 21: 7011-7026.
45. Cheng N, Brantley D, Fang WB, et al. Inhibition of vegf-dependent multistage carcinogenesis by soluble epha receptors. Neoplasia. 2003; 5: 445-456.
46. Cheng N, Brantley DM, Liu H, et al. Blockade of epha receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res. 2002; 1: 2-11.
47. Noren NK, Lu M, Freeman AL, et al. Interplay between ephb4 on tumor cells and vascular ephrin-b2 regulates tumor growth. Proc Natl Acad Sci U S A. 2004; 101: 5583-5588.
48. Munoz JJ, Alonso CL, Sacedon R, et al. Expression and function of the eph a receptors and their ligands ephrins a in the rat thymus. Immunol J. 2002; 169: 177-184.
49. Wu J and Luo H. Recent advances on t-cell regulation by receptor tyrosine kinases. Curr Opin Hematol. 2005; 12: 292-297.
50. Aasheim HC, Munthe E, Funderud S, et al. A splice variant of human ephrin-a4 encodes a soluble molecule that is secreted by activated human b lymphocytes. Blood. 2000; 95: 221-230.
51. Luo H, Yu G, Tremblay J and Wu J. Ephb6-null mutation results in compromised t cell function. Clin Invest J. 2004; 114: 1762-1773.
52. Freywald A, Sharfe N, Miller CD, et al. Epha receptors inhibit anti-cd3-induced apoptosis in thymocytes. Immunol J. 2006; 176: 4066-4074.
53. Sharfe N, Nikolic M, Cimpeon L, et al. Epha and ephrin-a proteins regulate integrin-mediated t lymphocyte interactions. Mol Immunol. 2008; 45: 1208-1220.
54. Konstantinova I, Nikolova G, Ohara-Imaizumi M, et al. Epha-ephrin-a-mediated beta cell communication regulates insulin secretion from pancreatic islets. Cell. 2007; 129: 359-370.
55. Kulkarni and Kahn CR RN. Ephs and ephrins keep pancreatic beta cells connected. Cell. 2007; 129: 241-243.
56. Teitelbaum SL and Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003; 4: 638-649.
57. Tondravi MM, McKercher SR, Anderson K, et al. Osteopetrosis in mice lacking haematopoietic transcription factor pu.1. Nature. 1997; 386: 81-84.
58. Felix R, Cecchini MG and Fleisch H. Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology. 1990; 127: 2592-2594.
59. Kodama H, Nose M, Niida S and Yamasaki A. Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. Exp Med J. 1991; 173: 1291-1294.
60. Yoshida H, Hayashi S, Kunisada T, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature. 1990; 345: 442-444.
61. Y-Kong Y, Yoshida H, Sarosi I, et al. Opgl is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999; 397: 315-323.
62. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93: 165-176.
63. Li J, Sarosi I, Yan XQ, et al. Rank is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A. 2000; 97: 1566-1571.
64. Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochemical and Biophysical Research Communications. 1998; 247: 610-615.
65. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell. 1997; 89: 309-319.
66. Harada S and Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. 2003; 423: 349-355.
67. Ducy P, Zhang R, Geoffroy V, et al. Osf2/cbfa1: A transcriptional activator of osteoblast differentiation. Cell. 1997; 89: 747-754.
68. Komori T, Yagi H, Nomura S, et al. Targeted disruption of cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997; 89: 755-764.
69. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002; 108: 17-29.
70. Zaidi M. Skeletal remodeling in health and disease. Nat Med. 2007; 13: 791-801.
71. Howard GA, Bottemiller BL, Turner RT, et al. Parathyroid hormone stimulates bone formation and resorption in organ culture: Evidence for a coupling mechanism. Proc Natl Acad Sci U S A. 1981; 78: 3204-3208.
72. Hayden JM, Mohan S and Baylink DJ. The insulin-like growth factor system and the coupling of formation to resorption. Bone. 1995; 17: 93S-98S.
73. Centrella M, McCarthy TL and Canalis E. Transforming growth factor-beta and remodeling of bone. J Bone Joint Surg Am. 1991; 73: 1418-1428.
74. Parfitt AM, Mundy GR, Roodman GD, et al. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res. 1996; 11: 150-159.
75. Sims NA, Jenkins BJ, Quinn JM, et al. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. Clin Invest J. 2004; 113: 379-389.
76. Nakamura M, Udagawa N, Matsuura S, et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology. 2003; 144: 5441-5449.
77. Hoff AO, Catala-Lehnen P, Thomas PM, et al. Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. Clin Invest J. 2002; 110: 1849-1857.
78. Ryu J, Kim HJ, Chang EJ, et al. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. Embo J. 2006; 25: 5840-5851.
79. Falany ML, AM Thames 3rd, McDonald JM, et al. Osteoclasts secrete the chemotactic cytokine mim-1. Biochem Biophys Res Commun. 2001; 281: 180-185.
80. Grano M, Galimi F, Zambonin G, et al. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proceedings of the National Acadamy of Sciences of the USA. 1996; 93: 7644-7648.
81. Zhao C, Irie N, Takada Y, et al. Bidirectional ephrinb2-ephb4 signaling controls bone homeostasis. Cell Metab. 2006; 4: 111-121.
82. Compagni A, Logan M, Klein R and Adams RH. Control of skeletal patterning by ephrinb1-ephb interactions. Dev Cell. 2003; 5: 217-230.
83. Davy A, Aubin J and Soriano P. Ephrin-b1 forward and reverse signaling are required during mouse development. Genes Dev. 2004; 18: 572-583.
84. Xing W, Govoni K, Kapoor A, et al. Targeted disruption of ephrin b1 in osteoblasts reduces bone size in mice. J Bone Miner Res. 2007; 22: 1107.
85. Wieland I, Jakubiczka S, Muschke P, et al. Mutations of the ephrin-b1 gene cause craniofrontonasal syndrome. Am Hum Genet J. 2004; 74: 1209-1215.
86. Twigg SR, Kan R, Babbs C, et al. Mutations of ephrin-b1 (efnb1), a marker of tissue boundary formation, cause craniofrontonasal syndrome. Proc Natl Acad Sci U S A. 2004; 101: 8652-8657.
87. Wieland I, Jakubiczka S, Muschke P, et al. Mapping of a further locus for x-linked craniofrontonasal syndrome. Cytogenet Genome Res. 2002; 99: 285-288.
88. Allan EH, Hausler KD, Wei T, et al. Ephrinb2 regulation by parathyroid hormone (pth) and pthrp revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res. 2008; [Epub ahead of print]
89. Wang Y, ElAlieh HZ, Chang W, et al. Ablation of igf-1 signaling disrupts the communication between osteoblasts and osteoclasts. J Bone Miner Res. 2007; 22: S241.
90. Xing W, Baylink D, Kesavan C, et al. Global gene expression analysis in the bones reveals involvement of several novel genes and pathways in mediating an anabolic response of mechanical loading in mice. Cell Biochem J. 2005; 96: 1049-1060.
91. Vaught D, Brantley-Sieders D and Chen J. Epha2 induced osteolysis: A novel mechanism for osteoclast activation mediated by breast cancer-bone cell interactions. Proceedings of the 9th Annual Meeting of the American Association for Cancer Research. 2008: 2523.
92. Bates AL, Mundy GR and Edwards CM. Myeloma cells decrease ephb4 expression in osteoblasts: A novel mechanism for regulation of bone formation in multiple myeloma. J Bone Miner Res. 2007; 22: S309.
93. Morrissey C, True LD, Roudier MP, et al. Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis. 2008; 25: 377-388.
94. Guenther R, Krenn V, Morawietz L, et al. Giant cell tumors of the bone: Molecular profiling and expression analysis of ephrin a1 receptor, claudin 7, cd52, fgfr3 and amfr. Pathol Res Pract. 2005; 201: 649-663.